Related Experiment Video
Updated: May 9, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Familial hypobetalipoproteinemia in pediatric patients with fatty liver: an under-recognized cause
Nurit Loberman Nachum1,2, Eyal Shteyer3,4, Hofit Cohen2,5
1Pediatric Gastroenterology and Nutrition Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.
Insights
Familial hypobetalipoproteinemia (FHBL) is an important consideration in children with fatty liver, especially when other causes are not apparent. Genetic evaluation can identify FHBL in pediatric fatty liver cases.
Area of Science:
- Pediatric Gastroenterology
- Clinical Genetics
- Hepatology
Background:
- Fatty liver is a prevalent cause of chronic liver disease in children, frequently linked to metabolic dysfunction-associated steatotic liver disease (MASLD).
- In lean or younger children, fatty liver may signal underlying genetic or metabolic disorders, including familial hypobetalipoproteinemia (FHBL).
Purpose of the Study:
- To highlight the significance of considering familial hypobetalipoproteinemia (FHBL) in the diagnostic workup of children presenting with fatty liver.
- To investigate the clinical characteristics and genetic basis of FHBL in a cohort of pediatric patients with fatty liver.
Main Methods:
- A case series involving seven patients diagnosed with FHBL across three families.
- Data collection included clinical, laboratory, imaging, and genetic information from medical records.
- Genetic evaluation focused on identifying variants in genes associated with lipid metabolism, specifically *MTTP* and *APOB*.
Main Results:
- The study identified FHBL in seven pediatric patients, with genetic analysis revealing *MTTP* variants in two siblings and *APOB* variants in five patients.
- Patients presented with fatty liver, and some had elevated liver enzymes and abnormal lipid profiles (triglycerides, LDL, apolipoprotein B).
- The mean BMI was 27 kg/m², with two patients classified as obese (BMI > 30 kg/m²).
Conclusions:
- Familial hypobetalipoproteinemia (FHBL) should be considered in the differential diagnosis for pediatric fatty liver.
- FHBL can coexist with other factors contributing to fatty liver, such as obesity.
Introduction:
Fatty liver is a leading cause of chronic liver disease in children, most often due to metabolic dysfunction-associated steatotic liver disease (MASLD). Fatty liver in lean or younger children may indicate underlying metabolic or genetic disorders, such as familial hypobetalipoproteinemia (FHBL). We examined the importance of considering familial hypobetalipoproteinemia (FHBL) in children presenting with fatty liver.
Methods:
This case series includes seven patients with FHBL from three families, treated at two medical centers. Clinical, laboratory, imaging, and genetic data were collected from the medical records.
Results:
Four patients were male. The mean age at diagnosis was 15.3 years (range: 4-38). All the index patients were children or adolescents presenting with fatty liver. Genetic evaluation revealed biallelic variants in the microsomal triglyceride transfer protein (MTTP) gene in two siblings and heterozygous variants in the apolipoprotein B (APOB) gene in five patients. The mean body mass index was 27 kg/m2, and two patients had a BMI above 30 kg/m2. The median follow-up (FU) time was 12 months (interquartile range [IQR]: 1-57 months). Liver enzymes were elevated in three patients (range: 50-300 IU/L); median aspartate aminotransferase and alanine aminotransferase levels were 30 IU/L (IQR: 26-40.75) and 32 IU/L (IQR: 24.5-74), respectively. The median triglyceride, low-density lipoprotein, and apolipoprotein B levels were 74 mg/dL (IQR: 62-125), 55.3 mg/dL (IQR: 30-84.5), and 39.5 mg/dL (IQR: 35.2-43), respectively.
Conclusion:
FHBL should be considered a potential diagnosis in children with fatty liver and may coexist with other contributing etiologies such as obesity.
Related Concept Videos
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Inborn Errors of Metabolism
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

